Ashling Wahner

Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management

May 7th 2025

Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.

Dr Morris on the Clinical Benefit With Nivolumab Plus Ipilimumab Across dMMR/MSI-H mCRC Subgroups

May 6th 2025

Van Karlyle Morris, MD, discusses the efficacy of nivolumab plus ipilimumab according to stratification factors in dMMR/MSI-H mCRC.

Dr Harding on the FDA Approval of Nivolumab Plus Ipilimumab for Unresectable or Metastatic HCC

May 6th 2025

James J. Harding, MD, discusses efficacy data with nivolumab plus ipilimumab that led to this regimen’s FDA approval for unresectable or metastatic hepatocellular carcinoma

NIAGARA Trial Validates Perioperative Durvalumab Approach in MIBC

May 6th 2025

Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.

DUO-E Post Hoc Analysis Suggests Potential for Biomarker-Optimized pMMR Endometrial Cancer Management

May 6th 2025

Shannon Westin, MD, MPH, FACOG, contextualizes data from an exploratory biomarker analysis of the phase 3 DUO-E trial in pMMR recurrent endometrial cancer.

RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA

May 5th 2025

Dr Pavlick discusses the investigation of RP1 plus nivolumab in patients with advanced melanoma who have received prior immune checkpoint inhibition.

FDA Issues Refusal to File Letter for Nogapendekin Alfa Inbakicept sBLA in BCG-Unresponsive Papillary NMIBC

May 5th 2025

A meeting has been requested to address the FDA's refusal to file an sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive papillary NMIBC.

Frontline Eftilagimod Alpha/Pembrolizumab Yields Favorable OS in PD-L1–Negative HNSCC

May 5th 2025

Treatment with eftilagimod alpha plus pembrolizumab produced a median OS of 17.6 months in the first line for patients with PD-L1–negative HNSCC.

FDA Grants Fast Track Designation to ISB 2001 in Relapsed/Refractory Multiple Myeloma

May 5th 2025

ISB 2001 has received fast track designation from the FDA for patients with relapsed or refractory multiple myeloma who received 3 or more prior therapies.

Targeted Therapy Developments and Screening Updates Broaden the NSCLC Treatment Paradigm

May 5th 2025

Alexis Chidi, MD, PhD, MSPH, emphasizes the importance of having more available targeted therapies and explains NSCLC screening eligibility criteria.

Zurletrectinib Receives Priority Review from NMPA for NTRK Gene Fusion+ Advanced Solid Tumors

May 2nd 2025

A priority review was granted to zurletrectinib in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL

May 2nd 2025

An sBLA seeking the approval of epcoritamab plus rituximab and lenalidomide for relapsed/refractory FL is planned to be submitted to the FDA.

Oncology Experts Highlight Top Takeaways From the 2025 AACR Annual Meeting

May 2nd 2025

Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.

RP1 Plus Nivolumab Represents the Next Frontier of Oncolytic Virus–Based Therapy for Melanoma

May 2nd 2025

Anna C. Pavlick, BSN, MSc, DO, MBA, discusses data for RP1 plus nivolumab and the evolving treatment landscape in advanced melanoma.

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

May 1st 2025

Revisit Every OncLive On Air Episode From April 2025

May 1st 2025

Read a recap of the episodes of OncLive On Air that aired in April 2025.

Dr Simpkins on the Predictive Utility of Cyclin E1 for Azenosertib Response in Ovarian Cancer

April 30th 2025

Fiona Simpkins, MD, discusses key findings from the phase 2 DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer.

Dr Pimenta on Adipogenesis Defects Characteristic of Dedifferentiated Liposarcoma

April 30th 2025

Erica Maria Pimenta, MD, PhD, discusses a study investigating potential defects in molecular pathways involved in adipocyte-specific differentiation

Lung Cancer Experts Highlight the Significance and Limitations of ADCs

April 30th 2025

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Early Ruxolitinib Initiation Increases Spleen Response Rates in Myelofibrosis

April 30th 2025

Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.